Ascendis Pharma (ASND) to List Ordinary Shares Directly on Nasdaq

Also connected April 8, Ascendis Pharma reported caller Week 52 information from the Phase 2 COACH proceedings evaluating operation therapy with once-weekly TransCon CNP and TransCon hGH successful children with achondroplasia. The institution said the information showed improvements beyond linear growth, including increases successful limb span, spinal canal dimensions, and little limb alignment. Mean changes successful limb span Z-scores were +1.02 for treatment-naive patients and +0.66 for antecedently treated patients, with implicit gains of 9.4 cm and 7.9 cm, respectively. The institution besides reported improvements successful interpedicular region and tibial femoral angle, indicating imaginable benefits successful reducing nervus compression and improving limb alignment, with each patients completing 52 weeks and remaining connected therapy.

Copyright: wavebreakmediamicro / 123RF Stock Photo

On April 7, 2026, Ascendis Pharma announced that Yuviwel, its TransCon CNP therapy, was granted orphan cause exclusivity by the FDA and is present commercially disposable successful the United States.

Ascendis Pharma A/S (NASDAQ:ASND) develops TransCon-based therapies for unmet aesculapian needs.

While we admit the imaginable of ASND arsenic an investment, we judge definite AI stocks connection greater upside imaginable and transportation little downside risk. If you're looking for an highly undervalued AI banal that besides stands to payment importantly from Trump-era tariffs and the onshoring trend, spot our escaped study connected the best short-term AI stock.

READ NEXT: 33 Stocks That Should Double successful 3 Years and Cathie Wood 2026 Portfolio: 10 Best Stocks to Buy. 

Disclosure: None. Follow Insider Monkey connected Google News.